Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform
ST. PAUL, Minn.–(BUSINESS WIRE)– Cardio Flow, Inc., a privately held commercial-stage medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), is pleased to announce the successful completion of its first commercial cases for its FreedomFlow® Orbital Atherectomy Platform following FDA clearance in late September.
Promising new research co-led by Ritu Raman, the d’Arbeloff Career Development Assistant Professor of Mechanical Engineering, and MIT collaborators aims to restore mobility for those who have lost muscle through disease or trauma.
Levita Magnetics today announced the world’s first commercial use for its MARS magnetic-assisted robotic surgery platform.
Moon Surgical today announced the successful completion of the first 10 laparoscopic surgeries with its Maestro system in France.
Interventional Systems announced that the FDA granted a new 510(k) clearance for its Micromate surgical robot system.
Scientists have a new tool to precisely illuminate the roots of nerve pain. The fibers could help with testing treatments for nerve-related pain.
A team of researchers from the National University of Singapore (NUS) engineered an innovative magnetic gel that promises to accelerate the healing of diabetic wounds, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.
While useful for killing pathogens including SARS-CoV-2, the lights may cause unwanted chemical reactions and should be used with ventilation, researchers say.